("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, ...
NeurAxis, Inc. announced that Molina Healthcare will cover its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, which is FDA-cleared for treating functional abdominal ...
Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis ...
NeurAxis reported a 50% revenue increase in Q4 2024, reaching approximately $800,000, with a cash balance of $3.7 million. NeurAxis, Inc. reported a significant revenue increase of approximately ...
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company ...
Revenues in 4Q24 increased approximately 50% versus 4Q23 Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis ...
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies ...
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company ...
We are thrilled to connect with you as we celebrate NeurAxis's remarkable achievements in 2024 and anticipate the exciting opportunities ahead. This is a pivotal time for our company as we strive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback